Alnylam Pharmace. buy Raymond James
Start price
01.11.24
/
50%
€254.50
Target price
01.11.25
€274.85
Performance (%)
54.18%
End price
02.11.25
€392.40
Summary
This prediction ended on 02.11.25 with a price of €392.40. With a performance of 54.18% the BUY prediction by Raymond_James was a big success. Raymond_James has a follow-up prediction for Alnylam Pharmace. where he still thinks Alnylam Pharmace. is a Buy. Raymond_James has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Alnylam Pharmace. | 6.498% | 6.498% | -1.582% |
| iShares Core DAX® | 4.367% | 4.830% | 8.167% |
| iShares Nasdaq 100 | -0.294% | 3.311% | 34.822% |
| iShares Nikkei 225® | -0.471% | 8.527% | 62.385% |
| iShares S&P 500 | 1.267% | 2.858% | 25.640% |
Comments by Raymond_James for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Raymond James from $275.00 to $298.00. They now have an "outperform" rating on the stock.
Ratings data for ALNY provided by MarketBeat
In the thread Trading Alnylam Pharmace.
Die von Raymond_James gewählte maximale Laufzeit wurde überschritten
Current prediction by Raymond_James for Alnylam Pharmace.
Stopped prediction by Raymond_James for Alnylam Pharmace.
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€247.40
02.08.24
02.08.24
€251.93
02.08.25
02.08.25
38.64%
03.08.25
03.08.25
